Intravenous dipyrone for the acute treatment of episodic tension-type headache: A randomized, placebo-controlled, double-blind study

AUTOR(ES)

Bigal, M.E., Bordini, C.A., Speciali, J.G.

FONTE

Brazilian Journal of Medical and Biological Research

DATA DE PUBLICAÇÃO

2002-10

RESUMO

Acute headaches are responsible for a significant percentage of the case load at primary care units and emergency rooms in Brazil. Dipyrone (metamizol) is easily available in these settings, being the most frequently used drug. We conducted a randomized, placebo-controlled, double-blind study to assess the effect of dipyrone in the acute treatment of episodic tension-type headache. Sixty patients were randomized to receive placebo (intravenous injection of 10 ml saline) or 1 g dipyrone in 10 ml saline. We used seven parameters of analgesic evaluation. The patients receiving dipyrone showed a statistically significant improvement (P<0.05) of pain compared to placebo up to 30 min after drug administration. The therapeutic gain was 30% in 30 min and 40% in 60 min. The number of patients needed to be treated for at least one to have benefit was 3.3 in 30 min and 2.2 in 60 min. There were statistically significant reductions in the recurrence (dipyrone = 25%, placebo = 50%) and use of rescue medication (dipyrone = 20%, placebo = 47.6%) for the dipyrone group. Intravenous dipyrone is an effective drug for the relief of pain in tension-type headache and its use is justified in the emergency room setting.

Documentos Relacionados

• Etanercept Treatment in Children With New-Onset Type 1 Diabetes: Pilot randomized, placebo-controlled, double-blind study
• Randomized, Placebo-Controlled, Double-Blind Trial To Evaluate the Efficacy of Mupirocin for Eradicating Carriage of Methicillin-Resistant Staphylococcus aureus
• Inhaled budesonide for adults with mild-to-moderate asthma: a randomized placebo-controlled, double-blind clinical trial
• A multiclinic, placebo-controlled, double-blind study of prostaglandin E1 in Raynaud's syndrome.
• Treatment of primary insomnia with melatonin: a double-blind, placebo-controlled, crossover study